HAS Healthcare Advanced Synthesis Secures Cerbios-Pharma Acquisition

HAS Healthcare Advanced Synthesis SA (HAS), an international leader in the development and production of pharmaceutical active ingredients, has announced its planned acquisition of Cerbios-Pharma SA, a global supplier of chemical and biological APIs, including the rapidly growing sector of drug-antibody conjugates. Both companies, headquartered in Switzerland, aim to form a leading international Contract Development and Manufacturing Organization (CDMO) with the support of 65 Equity Partners, which now holds a 40% stake. The acquisition is subject to regulatory and tax approvals. This transaction marks a strategic step towards strengthening their global position and offering enhanced services to the evolving pharmaceutical industry, especially in oncology, neurology, endocrinology, and other therapeutic areas. The merged entity seeks to leverage strong sectoral trends, including an increasing demand for complex therapies, supported by demographic changes and continuous scientific discoveries. Both companies continue to be driven by their strong cultures and remain committed to their regional presence in Ticino.